Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Grail

3 Biotech Stocks With Anticipated Strong Earnings Reports

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

StockNews.com

The Canyon Grail CF SLX 8 AXS is one of the best gravel bikes I have ever tested but I would never buy one

Canyon’s Grail is an optimized gravel racing machine, but is it the pinnacle of gravel tech or death by integration?

Bike Perfect

What You Need to Know Ahead of Illumina's Earnings Release

Illumina is expected to release its second-quarter earnings next month, analysts expect a double-digit earnings dip.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biopharma Stocks to Buy for Long-Term Growth

With the rising investment in personalized medicine research and development and growing clinical trials, the biopharma industry’s prospects appear promising. Hence, quality biotech stocks, Alnylam Pharmaceuticals (ALNY), Illumina (ILMN), and Gilead Sciences (GILD) with long-term growth might be solid buys. Read more….

StockNews.com

3 Biotech Stocks to Monitor for May Moves

The biotech industry is well poised to flourish, buoyed by its strong emphasis on technology-driven advancements to address complex medical challenges and government funding. Hence, quality biotech stocks Harmony Biosciences Holdings (HRMY), Illumina (ILMN), and Compugen (CGEN) could be ideal watchlist additions for May. Read more….

StockNews.com

'You Know You’ve Still Got To Go Through Hell To Get There, But If You Can Get It At Stage 2 or 3'... Hall Of Famer Juli Inkster On New Cancer Screening

Are we entering a new worldwide era for cancer screening?

Golf Monthly

Illumina Ends Its Controversial Grail Battle With A Divestiture; Shares Rise

Illumina stock rose Monday after the company said it would divest its cancer detection outfit, Grail, following a lengthy court battle.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Illumina To Sell Grail After U.S. Antitrust Ruling

Illumina said Sunday it will the sell cancer detection startup after a U.S. appeals court said the $7.1 billion deal violated antitrust laws,

Investors Business Daily

Illumina Sheds Light, Divests its Cancer Tester, Grail

Illumina, a beacon in genetic science, is set to unfurl its stake in Grail-the stellar creator of cancer-detecting tests–in a dance of corporate divestiture.

Top News

3 Healthcare Stocks to Buy With Major Value Behind Them

The healthcare industry is set for growth due to the growing demand for quality healthcare services and the integration of advanced technologies in offerings and operations. Therefore, it could be wise to buy fundamentally strong medical stocks HCA Healthcare (HCA), LifeVantage (LFVN), and Semler Scientific (SMLR). Read more….

StockNews.com

DNA-Reading Giant Illumina Crashes As Macro Pressures Guidance — Again

Illumina stock crashed Friday after the DNA-reading behemoth slashed its outlook as pressures continue to build on life sciences companies.

Investors Business Daily

EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail

The European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators

The Independent UK

Inside Illumina’s bruising proxy battle with billionaire activist investor Carl Icahn

Illumina’s contentious acquisition of cancer test maker Grail brought billionaire Carl Icahn to the company’s doorstep.

Fortune

EU fines US firm Illumina $475 million for jumping gun on buying cancer-screening company Grail

The European Union has slapped a $475 million fine on U.S. biotech giant Illumina for buying out cancer-screening company Grail without the approval of the 27-nation bloc’s antitrust watchdog

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Businessweek

Illumina’s Sudden CEO Exit Is Just One of Many Problems Facing DNA Company

The sudden resignation of Francis deSouza raises questions about the firm’s future after its proxy fight with Carl Icahn.

Fortune

Carl Icahn’s activist play plays into the hands of Lina Khan and EU regulators

Every company with acquisition plans in the U.S. and Europe should be concerned about the FTC partnering with EU regulators to sink the Illumina-Grail deal.

Bike Perfect

Canyon Grail CF SL 7 eTap review – gravel bike with a need for speed

We put one of Canyon's fast and light gravel bikes to the test and see how it rides outside its comfort zone

Investors Business Daily

Illumina Stock Tumbles As Sales, Profits Decline — Why The First-Quarter Beat Has 'Mixed Implications'

DNA-sequencing leader Illumina eked out a first-quarter beat, but ILMN stock toppled Wednesday on its cloudy future.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

FTC Orders Biotech Illumina To Unwind Grail Deal Amid Icahn Battle

The FTC ordered Monday that biotech firm Illumina must unwind its $8 billion purchase of the cancer-testing startup Grail. ILMN stock fell on the news.

Investors Business Daily

Illumina Surges As Activist Investor Carl Icahn Attempts To Wrest Control

Activist investor Carl Icahn is fighting for control of Illumina after the acquisition of Grail. In response, ILMN stock surged Monday.

Investors Business Daily

Illumina's Woes Mount As Guidance Lags And Grail Controversy Continues

Illumina stock plunged to its lowest point in three months Tuesday after the gene-sequencing giant issued a disappointing outlook for 2023.

Fortune

A frozen capital market and an insurance premium shock: 10 health care predictions for 2023 from top investors

Distressed deals, inflation in insurance premiums, and restrictions on transgender treatments. Here's what the health care sector will look like in 2023, according to top investors.

The Conversation

A blood test that screens for multiple cancers at once promises to boost early detection

Detecting cancer early before it spreads throughout the body can be lifesaving. This is why doctors recommend regular screening for several common cancer types, using a variety of methods. Colonoscopies, for example, screen for colon cancer, while mammograms screen for breast cancer.

Tribune News Service

Faye Flam: Better cancer screenings are coming. Can we afford them?

Patients and their doctors count on cancer screening tests to save lives, and yet a number of large, controlled studies are showing disappointing results for mammography and other mass screening tests. This month, the New England Journal of Medicine published a controversial study that cast doubt on the widely accepted…

The Street

Illumina's Singapore Tax Holiday is About to Expire

The DNA sequencing giant generated over 10% of its diluted earnings per share in 2021 from a tax holiday.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.